Project Grant R01DA064583
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Johns Hopkins University a $194,271 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and optimize rodent models for studying cannabis drug discrimination, drug-seeking behavior, and self-administration of vaporized cannabis extracts. The two-year project, effective May 1, 2026 through April 30, 2028, addresses the critical gap in preclinical research models needed to...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Johns Hopkins University a Project Grant totaling $465,250 under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a human laboratory study investigating pregnenolone as a treatment for cannabis intoxication. The research project, which commenced September 1, 2025 and concludes August 31, 2027, will assess whether pregnenolone—a negative allosteric modulator of the CB1 cannabinoid...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Medical University of South Carolina a Project Grant totaling $686,692 under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct prospective research on cannabis use reduction and its impact on patient functioning. Initiated on September 1, 2025, and extending through July 31, 2030, this eight-week clinical trial will enroll 176 adults aged 18 and older with Cannabis Use Disorder...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Icahn School of Medicine at Mount Sinai a $1.014 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on the epigenetic basis of tetrahydrocannabinol (THC) consumption. The award, effective September 1, 2025, through May 31, 2030, supports fundamental research aimed at understanding the neurobiological mechanisms underlying cannabis use disorder (CUD)—a...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a Project Grant of $732,747 to Boston University Medical Campus on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports a research project titled "Quantifying Health Effects of Cannabis Use and Cannabis Use Disorder on Geriatric Syndromes and HIV Outcomes: Causal Effects Analysis in the Veterans Aging Cohort Study and the Mt. Sinai HIV Cohort,"...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $1.765 million Project Grant to the University of Alabama at Birmingham on April 15, 2026, with a completion date of January 31, 2031. This award funds research investigating the impact of cannabis use on T cell function and HIV (Human Immunodeficiency Virus) persistence within the central nervous system (CNS) reservoir. The research...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a $647,142 Project Grant to The University of Kentucky Research Foundation, effective February 15, 2026, through November 30, 2030, under the Drug Use and Addiction Research Programs (CFDA 93.279). This award funds two randomized, double-blind, placebo-controlled clinical research studies examining the impact of cannabis on opioid self-administration in individuals with moderate-to-severe opioid use...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Boston Children's Hospital a $489,500 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning June 1, 2025 and concluding May 31, 2027. This research initiative develops and validates remote oral fluid testing procedures to assess cannabis non-use as a key outcome measure in clinical trials targeting younger adults aged 18-30 years with cannabis use disorder (CUD). The project...
- This $668,110 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and acceptability testing of a technology-based intervention to reduce cannabis misuse among college students. The project aims to refine an existing intervention that provides information on cannabis products, marketing, laws, and risks to increase young adults' cannabis literacy. The research will involve focus groups with...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Regents of the University of Colorado-Denver a $703,662 Project Grant on July 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct translational research examining the mechanisms by which prenatal cannabis exposure affects child growth and metabolic outcomes. The research combines large-scale epidemiologic investigation with in vitro experimental work, leveraging two...
The National Institute on Drug Abuse (NIDA) awarded The Johns Hopkins University a $708,190 Project Grant effective July 1, 2026 through May 31, 2031 under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant funds a clinical research initiative examining the pharmacokinetic and pharmacodynamic effects of varying tetrahydrocannabinol (THC) to cannabidiol (CBD) ratios in oral cannabis products commonly found in the retail marketplace. The research comprises two double-blind, placebo-controlled human laboratory studies designed to characterize how different THC:CBD ratios and THC dose levels influence THC absorption, subjective intoxication, cognitive and psychomotor impairment, and cardiovascular effects in human subjects. The project addresses a significant gap in controlled clinical research regarding cannabis edibles formulations. Aim 1 will evaluate six different THC:CBD ratio conditions (1:0, 1:1, 1:5, 1:10, 1:30, and 0:1) at a fixed 10-milligram THC dose, while Aim 2 will characterize dose-dependent effects across four THC dose levels combined with CBD at an ecologically-valid 1:30 THC:CBD ratio. Study findings are expected to inform understanding of how product formulation influences THC-related acute adverse effects and may contribute to evidence-based cannabis product regulation and public health policy guidance.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $708.2k | 6/23/26 |